Antibodies Used to Support Research into the Treatment of Ulcerative Colitis and Crohn’s Disease

HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the release of a range of anti-vedolizumab antibodies.

Vedolizumab (Entyvio) is a monoclonal antibody that is used to treat ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Bio-Rad’s anti-vedolizumab antibodies, which support research into the treatment of these diseases, include four recombinant monoclonal anti-idiotypic antibodies that are highly specific for the humanized IgG1 kappa antibody drug, vedolizumab, and are suitable for development of bioanalytical and patient monitoring assays.

Bio-Rad’s recombinant monoclonal anti-vedolizumab antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display, resulting in highly targeted reagents. The paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them ideal for development of a pharmacokinetic bridging ELISA to monitor free drug levels, or as reference standards in anti-drug antibody assays. The recombinant production method ensures a consistent and secure supply.

“We are pleased to introduce the anti-vedolizumab antibodies, an exciting addition to Bio-Rad’s industry-leading portfolio of anti-biotherapeutic antibodies,” said Amanda Turner, Product Manager, Custom Antibody Products at Bio-Rad. “We are now able to offer a reliable source of antibodies for the development of bioanalytical assays for vedolizumab, to support research into the treatment of ulcerative colitis and Crohn’s disease.”

Bio-Rad’s anti-vedolizumab antibodies are approved for in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development and patient monitoring.

For more information about Bio-Rad’s anti-vedolizumab antibodies https://www.bio-rad-antibodies.com/anti-vedolizumab-antibody-entyvio.html

 

Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. HuCAL and CysDisplay are trademarks of MorphoSys AG.  

 

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio-rad.com.

 

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “can,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

To read the full story...

Already a subscriber? Login now

< | >